The risk of cancer in subjects with and without DM.

<p>Abbreviations: HR, hazard ratio.</p><p>^†p< 0.05 for comparison between subjects with DM and without DM.</p><p>^‡p< 0.001 for comparison between subjects with DM and without DM.</p><p>^aSex, age, hypertension, dyslipidemia, obesity, gout, hepatitis B, hepatitis C, and liver cirrhosis were adjusted for the cancer risk analysis.</p><p>The risk of cancer in subjects with and without DM.</p

Effects of oral ADT on the risk of cancer among T2DM patients.

<p>Abbreviations: ADT, anti-diabetic therapy; CI, confidence interval; HRs, hazard ratios.</p><p>Cancer incidence density: the number of incident cancer events per 10,000 person-years.</p><p>^†p< 0.05 for comparison between T2DM patients treated with and without oral ADT.</p><p>^aData presented as the T2DM patients treated with and without oral ADT.</p><p>^bAdjusted for sex, age, hypertension, dyslipidemia, obesity, gout, hepatitis B, hepatitis C, liver cirrhosis, and duration of ADT exposure which was treated as a time dependent variable.</p><p>Effects of oral ADT on the risk of cancer among T2DM patients.</p

Adjusted hazard ratios (AHRs) of cancer in DM patients with and without insulin injection.

<p>AHRs: Adjusted for sex, age, hypertension, dyslipidemia, obesity, gout, hepatitis B, hepatitis C, liver cirrhosis, and duration of insulin injection exposure which was treated as a time dependent variable.</p><p>Adjusted hazard ratios (AHRs) of cancer in DM patients with and without insulin injection.</p

The characteristics of patients with DM (n = 36270).

<p>Abbreviations: CI, confidence interval, hazard ratio.</p><p>^†p< 0.05,</p><p>^‡p< 0.001</p><p>^aSex, age, hypertension, dyslipidemia, obesity, gout, hepatitis B, hepatitis C, and liver cirrhosis were adjusted for the cancer risk analysis.</p><p>^bThe comparison between subjects with DM and without DM.</p><p>^cThe comparison between subjects with T1DM and without DM.</p><p>^dThe comparison between subjects with T2DM and without DM.</p><p>The characteristics of patients with DM (n = 36270).</p

The study design of case cross-over: 1) Hazard period: patients who had been diagnosed with fractures, 2) Control period: patients who had not been diagnosed with fractures, 3) Washout period: 5 weeks for the washing out of residues of drug reaction.

<p>The study design of case cross-over: 1) Hazard period: patients who had been diagnosed with fractures, 2) Control period: patients who had not been diagnosed with fractures, 3) Washout period: 5 weeks for the washing out of residues of drug reaction.</p

Flowchart for the selection of the sample from the National Health Insurance Research Dataset.

<p>Flowchart for the selection of the sample from the National Health Insurance Research Dataset.</p

Cumulative incidence curve for total mortality according to the contribution of DFAα1 using competing risk model.

<p>The survival significant decreased if the DFAα1 was below 0.95.</p

Linear and nonlinear heart rate variability parameters of the study subjects in mortality and survival groups.

<p>Linear and nonlinear heart rate variability parameters of the study subjects in mortality and survival groups.</p

Multivariate subdistribution hazard model by using clinical factors and DFAα1 as predictor for cardiac mortality and total mortality.

<p>Multivariate subdistribution hazard model by using clinical factors and DFAα1 as predictor for cardiac mortality and total mortality.</p

Basic characteristics of the study subjects in mortality and survival groups.

<p>Basic characteristics of the study subjects in mortality and survival groups.</p